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Objective: Early treatment choice is critical in first-episode schizophrenia-spectrum disorders. The purpose of this study was 
to describe prescribing trends of antipsychotics use in patients with first-episode schizophrenia in 2005 and 2010, respectively.
Methods: We reviewed the medical records of newly treated patients with schizophrenia from a university psychiatric hospital 
in 2005 (n=47) and 2010 (n=52). We defined patients as receiving a high antipsychotic dose if their ratio of prescribed daily 
dose (PDD) to defined daily dose (DDD) was greater than 1.5.
Results: The rates of high-dose antipsychotic prescription were 61.7% and 53.8% in 2005 and 2010, respectively. The rates 
of antipsychotic polypharmacy were 34.6% in 2005 and 34.0% in 2010. The most common first-prescribed antipsychotics were 
(in descending order of prescription frequency) olanzapine, risperidone, aripiprazole, and haloperidol in 2005 and risperidone, 
quetiapine, paliperidone, and olanzapine in 2010. High-dose antipsychotics were significantly associated with antipsychotic poly-
pharmacy (odds ratio=23.97; p＜0.01). More individuals were treated with mood stabilizers in 2010 than in 2005 (p=0.003).
Conclusion: The practice of prescribing high-dose antipsychotics and associated antipsychotic polypharmacy were common 
even for initial treatment of first-episode schizophrenia in 2005 and 2010. In 2010, the list of the most common first-prescribed 
antipsychotics changed, and the use of mood stabilizers increased in non-affective schizophrenia.
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INTRODUCTION
The onset of schizophrenia illness typically occurs in 
late adolescence or early adulthood, with patients showing 
neurodevelopmental alterations as well as a progressive 
decline in overall functions.1) The deterioration is evident 
in psychopathological, neurocognitive, and functional 
areas following the initial onset of a psychotic episode. 
Lifetime maintenance therapy may improve social func-
tioning and prevent symptom relapse; however, the ther-
apy also causes significant public health problems and 
economic costs.2) Pharmacological intervention is most 
efficacious during the first 5 years of illness,3) and the 
chance of responding to treatment decreases over time.4) 
The initial response to medication within the first 1-3 
months is highly predictive of long-term disease conse-
quences.5) In this context, the choice of antipsychotic drug 
is important for first-episode psychosis treatment. 
Despite numerous trials investigating first-episode psy-
chosis treatment, no specific drug has been proven to be 
superior in terms of overall efficacy, with the exception of 
clozapine in patients with neuroleptic-refractory schizo-
phrenia.6) Currently, schizophrenia treatment guidelines 
recommend second-generation antipsychotics (SGAs) as 
first-line medications,7-9) as they are associated with fewer 
extrapyramidal symptoms (EPS) and other favorable side 
effect profiles. The trend toward more frequent use of 
SGAs over first-generation antipsychotics (FGAs) from 
the 1990s to the early 2000s has been reported in many 
countries.10,11) However, little is known about the more re-
cent changes in the prescription pattern of antipsychotics 
for first-episode schizophrenia after this shift toward in-
creasing SGA use. 
Patients with first-episode schizophrenia are more sen-
sitive to a given dose of antipsychotics than chronic 
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patients.12) According to a meta-analysis,13) mean effec-
tive doses are up to 50% lower in first-episode schizo-
phrenia than in chronic schizophrenia. However, it is not 
uncommon for the patients to be given doses that exceed 
the recommended therapeutic doses.14,15) Despite con-
sistent recommendations for antipsychotic mono-
therapy,7,8,12) the practice of prescribing multiple anti-
psychotic drugs appears to be increasing,11) and an associ-
ation between antipsychotic polypharmacy and high 
doses of prescribed antipsychotics has been observed.16,17) 
Although the use of high-dose prescription and poly-
pharmacy has been studied in chronic patients with schiz-
ophrenia, relatively few studies have investigated these 
treatment strategies in the early stages of the disease.
The present study aimed (1) to examine changes in the 
prescribing patterns of antipsychotics and other psycho-
tropic drugs between 2005 and 2010, and (2) to identify 
the relationships among dosage, antipsychotic poly-
pharmacy, and other clinical correlates in patients with 
first-episode schizophrenia who were discharged from a 
university psychiatric hospital.
METHODS
Study Settings
This study was carried out at Severance Mental Health 
Hospital, a locked psychiatric inpatient facility located 
near Seoul and a part of the Unit of Psychiatry in Yonsei 
University Health System (YUHS). This residency-affili-
ated facility admits patients transferred from two other 
YUHS outpatient units in Seoul and several other mental 
health centers throughout the country, offering short- to 
medium-term care for patients with acute and subacute 
psychiatric conditions. This study was approved by the 
Institutional Review Board of Severance Mental Health 
Hospital.
Data Source and Study Population
Data specified according to protocol were collected ret-
rospectively from patient medical records by manual 
search. Available medical records of all patients with a di-
agnosis of schizophrenia or schizophreniform disorder 
(the Diagnostic and Statistical Manual of Mental Disorders 
4th edition, text revision [DSM-IV-TR])18) who were dis-
charged from the hospital between January 1, 2005 and 
December 31, 2010 were analyzed. We excluded data 
from patients who had a prior history of psychotic epi-
sodes before the most recent episode leading to admission. 
The year 2005 was chosen as most major atypical anti-
psychotics (including aripiprazole, which was approved 
by the Korea Food and Drug Administration [KFDA] for 
the treatment of schizophrenia in 2004) had become com-
mercialized by 2005 in Korea. The year 2010 was chosen 
as it was the most recent year from which all medical re-
cords were available at the time of investigation. 
Patient medical records were checked for disease-specific 
information (length of stay, voluntary or involuntary treat-
ment) and demographic data (such as sex, age, and socio-
economic status). Comprehensive medication profiles in-
cluded antipsychotics, mood stabilizers, antidepressants, 
and benzodiazepines. “As needed” medication pre-
scriptions were excluded from consideration. The pre-
scription status of psychotropic drugs at the time of dis-
charge was chosen for analysis. We defined antipsychotic 
polypharmacy as the concurrent receipt of two or more 
chemically distinct antipsychotic drugs for at least 14 
days. A wide time window of at least 14 days and the pre-
scription status at the time of discharge (after the patient 
was mostly stable) were utilized to help reduce over-
estimation of polypharmacy. 
Data Analysis
To compare doses of different drugs, the prescribed dai-
ly dose (PDD) was divided by the defined daily dose 
(DDD) to yield a PDD/DDD ratio. DDD is the interna-
tional unit approved by the World Health Organization for 
drug use studies19) and is defined as “the assumed average 
maintenance dose per day for a drug used for its main in-
dication in adults.” A PDD/DDD ratio was then calculated 
as the sum of the individual PDD/DDD ratios of all anti-
psychotics prescribed to each determinate patient. To 
maintain consistency with previous studies,16,17) a high 
dose was defined as a PDD/DDD ratio of greater than 1.5.
Continuous variables were analyzed parametrically us-
ing t-tests. The chi-squared test was used to compare per-
centages of discrete variables, and Fisher’s exact test was 
used whenever appropriate. Logistic regression analysis 
was used to adjust for relevant covariates and to identify 
factors associated with high-dose antipsychotic prescrip-
tions. Initially, potential variables associated with high- 
dose antipsychotic prescriptions (age, sex, length of hos-
pital stay, socioeconomic status, anticholinergics, anti-
depressants, antipsychotics polypharmacy, benzodiaze-
pines, mood stabilizers, and year of institutionalization) 
were selected based on the results of prior studies.14,20) 
After univariate logistic regression, only factors with a 
significance of p＜0.20 (age, sex, socioeconomic status, 
mood stabilizer use, typical antipsychotics use, anti-
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Table 1. Sociodemographic and clinical characteristics of individuals diagnosed with schizophrenia for the first time in 2005 and 2010
Variable 2005 (n=47) 2010 (n=52) χ2/t p value
Age (yr) 35.3±12.6 32.5±12.9 1.096 0.276
Sex 　 　 　 　
Male 15 (31.9) 17 (32.7) 0.007 0.934
Female 32 (68.1) 35 (67.3) 　 　
Education (yr) 13.3±2.4 14.2±2.5 −1.805 0.074
Social economic status 　 　 　 　
Professional 0 (0) 4 (9.3) 6.912 0.141
Intermediate 8 (17.0) 6 (14.0) 　 　
Skilled non-manual/manual 26 (55.3) 27 (62.8) 　 　
Semi-skilled manual 10 (21.3) 4 (9.3) 　 　
Unskilled manual 3 (6.4) 2 (4.7) 　 　
Schizophrenia diagnostic subtype 　 　 1.35 0.717
Paranoid 34 (72) 38 (72.7) 　 　
Disorganized 1 (2.1) 2 (3.0) 　 　
Catatonic 0 (0) 1 (1) 　 　
Undifferentiated or schizophreniform disorder 12 (25.5) 11 (23.2) 　 　
Length of hospital stay (day) 55.6±55.5 46.1±27.3 1.088 0.279
Admission method 　 　 　 　
Voluntary 1 (2.1) 15 (29.4) 13.328 ＜0.001
Involuntary 46 (97.9) 36 (70.6) 　 　
Values are presented as mean±standard deviation or number (%).
t=t-test; χ2=chi-square test.
Fig. 1. Proportion of the antipsychotic drug first prescribed after 
initial schizophrenia diagnosis in 2005 and 2010 (*p＜0.05).
psychotic polypharmacy, and year of institutionalization) 
were inserted into the second logistic regression analysis. 
The Hosmer-Lemeshow goodness-of-fit test was used to 
assess the overall fit of the logistic regression model. All 
tests were two-tailed. Statistical analyses were carried out 
using the PASW Statistics software, ver. 18.0 (IBM Co., 
Armonk, NY, USA), and differences of p＜0.05 were con-
sidered significant.
RESULTS
Subjects
For this study, 47 and 52 newly treated patients with 
schizophrenia were enrolled in 2005 and 2010, respectively. 
Patient demographic and clinical characteristics are 
shown in Table 1. There were no differences in the 2005 
and 2010 patient groups in terms of sex, age, educational 
level, socioeconomic status, diagnostic subtype of schizo-
phrenia, or length of hospital stay. The rate of involuntary 
admissions decreased from 97.9% in 2005 to 70.6% in 
2010 (χ2=13.328; p＜0.001).
First-prescribed Antipsychotic Medication
Fig. 1 shows the first antipsychotic drug obtained from 
the pharmacy after schizophrenia diagnosis. In 2005, the 
four most common first-prescribed antipsychotics were 
olanzapine (34.0%), risperidone (34.0%), aripiprazole 
(23.0%), and haloperidol (19.1%). In 2009, a new atypical 
antipsychotic drug, “paliperidone,” was introduced after 
KFDA approval for the treatment of schizophrenia. In 
2010, the list of commonly prescribed antipsychotics 
changed to risperidone (36.5%), quetiapine (23.1%), pal-
iperidone (23.1%), and olanzapine (17.3%). There were 
no significant changes in the prescription of FGAs (levo-
mepromazine, chlorpromazine), zotepine, risperidone, 
olanzapine, clozapine, and amisulpride from 2005 to 2010 
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Table 2. Distribution of psychotropic drugs use in patients diagnosed in 2005 and 2010
Treatment 2005 (n=47) 2010 (n=52) χ2 p value*
High dose of antipsychotics 29 (61.7) 28 (53.8) 0.624 0.430
Antipsychotic polypharmacy 16 (34.0) 18 (34.6) 0.004 0.952
1st generation antipsychotics 12 (25.5)  7 (13.5) 2.319 0.128
2nd generation antipsychotics 46 (97.9) 52 (100) - 0.475†
Anticholinergics 25 (53.2) 27 (51.9) 0.016 0.900 
Antidepressants 3 (6.4) 4 (7.7) - 0.800† 
Benzodiazepines 30 (63.8) 27 (51.9) 2.564 0.278 
Mood stabilizers 0 (0.0) 9 (17.3) - 0.003†
Values are presented as number (%).
*p value on the basis of chi-square test (χ2) or †Fisher’s exact test.
Table 3. Factors associated with high-dose antipsychotic 
prescription (combined data from 2005 and 2010)
Factors p value
Odds 
ratio
95% confidence 
interval
Young age (＜35 yr) 0.335 1.766 0.556-5.608
Sex (male) 0.321 1.840 0.552-6.133
Low socioeconomic status 0.326 2.071 0.484-8.865
Mood stabilizer use 0.817 1.306 0.136-12.552
Number of typical 
antipsychotics use
0.656 1.777 0.142-22.251
Antipsychotic polypharmacy 0.008 23.965 2.313-248.332
Year of institutionalization (2005) 0.875 1.102 0.329-3.695
(Fig. 1). However, the rate of haloperidol prescription de-
creased from 19.1% in 2005 to 1.9% in 2010 (Fisher’s ex-
act test; p=0.006), and the rate of quetiapine prescription 
increased from 6.2% in 2005 to 27.4% in 2010 (χ2= 
31.434; p＜0.001). 
Prescription of Psychotropic Medications
The practice of antipsychotic polypharmacy and high 
dose of antipsychotics was similar in 2005 and 2010. A to-
tal of 61.7% and 53.8% patients were prescribed high 
doses of antipsychotics in 2005 and 2010, respectively 
(Table 2), and 34.6% and 34.0% of patients were pre-
scribed with antipsychotic polypharmacy in 2005 and 
2010, respectively. The most frequently prescribed drug 
within the antipsychotics combinations changed from hal-
operidol in 2005 (50.0%) to quetiapine in 2010 (50.0%). 
Prescription of FGAs and SGAs were not significantly 
different between these years. Prescription of anti-
cholinergics, antidepressants, and benzodiazepines was 
unchanged between 2005 and 2010; however, pre-
scription of mood stabilizers increased from 0.0% in 2005 
to 17.3% in 2010 (Fisher’s exact test; p=0.003). 
Factors Associated with High Doses of Antipsychotics
Prescription of high-dose antipsychotics was not asso-
ciated with patient age, sex, socioeconomic status, mood 
stabilizer use, typical antipsychotics use, or year of in-
stitutionalization (Table 3). Antipsychotic polypharmacy 
was most strongly associated with high doses of anti-
psychotics (odds ratio=23.965; 95% confidence interval 
2.313-248.332; p=0.008). According to the Hosmer- 
Lemeshow goodness-of-fit statistics, the reliability of the 
model was adequate (χ2=3.645; p=0.373).
DISCUSSION
The purpose of this study was to describe prescription 
trends for antipsychotics use and related drugs in patients 
with first-episode schizophrenia by comparing prescribed 
medications between the years of 2005 and 2010. In the 
present study, the overall rate of high-dose antipsychotic 
prescription during the initial inpatient treatment of 
first-episode schizophrenia was more than 60% in 2005 
and was similarly high in 2010. Furthermore, both time 
points showed antipsychotic polypharmacy rates of more 
than 34%, and polypharmacy was strongly associated 
with high-dose prescriptions after controlling for other 
clinical variables. 
Many reasons may explain the intensified treatments of 
high-dose antipsychotics in addition to antipsychotic pol-
ypharmacy, despite little scientific evidence to support 
these treatments. Increasing the dosage and combining 
different antipsychotics is one of several options that may 
be chosen when the response to initial prescriptions is in-
sufficient, and high-dose prescriptions may initially be ap-
plied if assuming an accelerated response. Furthermore, 
psychiatrists may begin to prescribe higher doses of SGAs 
even for initial treatment in first-episode psychosis due to 
experiences with SGAs causing less-pronounced dose- 
dependent EPS.21) 
Although no high-quality scientific evidence proves 
that high-dose therapy is beneficial,22-24) higher doses of 
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SGAs may be justified in certain cases, as they may im-
prove psychotic symptoms and optimize D2 receptor 
blockade if they are titrated close to the peak of their daily 
dose range.25) A recent study26) shows that high-dose 
SGAs modestly enhance treatment response and should 
be considered a viable treatment option for first-episode 
schizophrenia patients. This may contribute to the use of 
higher doses overall, particularly in individuals who have 
been prescribed multiple SGAs. However, the titration of 
antipsychotic doses should be carefully considered based 
on relevant clinical characteristics of individual patients 
due to the uncertain consequences of high-dose therapy.
Our findings suggest that SGAs (97.9% in 2005 and 
100% in 2010) have rapidly displaced the older first-gen-
eration neuroleptics in the initial treatment of schizo-
phrenia in Korea more so than in other countries.21,27,28) 
According to a recent comprehensive meta-analysis,29) 
several SGAs were shown to have a significantly lower 
treatment discontinuation than FGAs in first-episode 
schizophrenia patients irrespective of cause, negative 
symptoms, and global cognition, despite SGAs causing 
more weight gain. Although SGAs are preferred in treat-
ment recommendations, convincing evidence of an effi-
cacy difference between FGAs and SGAs in treating a first 
episode of psychosis is still lacking.30) While most studies 
are post hoc, SGAs studies are often industry-sponsored 
and tend to have a subtle bias against FGAs in total symp-
tom reduction and response rate.29) According to an up-
date by the National Institute for Health and Clinical 
Excellence, treatment guidelines are beginning to move 
away from previous recommendations of SGAs as the 
first-line drugs in patients with first-episode psychosis.31) 
Thus, the choice of antipsychotic drug in new-onset schiz-
ophrenia treatment may be influenced more by the drug’s 
side-effect profile than its efficacy.32) 
In the present study, olanzapine was the most com-
monly prescribed initial antipsychotic medication in 
2005, yet it was only the fourth most common in 2010. 
This change in prescribing pattern may reflect increasing 
concerns about weight gain and metabolic disturbances, 
which are the most frequent and harmful long-term side 
effects of SGAs.33) Although no data has associated meta-
bolic harm with first-response medication in young schiz-
ophrenic patients, all other SGAs except for clozapine are 
likely less harmful than olanzapine.34,35) The recently up-
dated Schizophrenia Patient Outcomes Research Team 
(PORT) guidelines recommended specifically against us-
ing olanzapine (or clozapine) as a first-line treatment for 
first-episode psychosis due to its substantial contribution 
to weight gain and metabolic abnormalities.36)
Our data showed that the most frequently prescribed 
drug within antipsychotic combinations changed from 
haloperidol in 2005 (50.0%) to quetiapine in 2010 (50.0%). 
This finding is consistent with the recent trend of quetia-
pine as the most frequently co-prescribed drug.21,37,38) 
Furthermore, 78.8% of quetiapine prescriptions in combi-
nation with other antipsychotics were at doses of lower 
than 300 mg/day. This may indicate in part that the drug’s 
compounds were often used in conjunction with other an-
tipsychotics as a potent sedative,39) rather than its anti-
psychotic properties. However, a recent meta-analysis 
warns that patients with schizophrenia are particularly 
sensitive to quetiapine-induced metabolic abnormalities, 
even at low doses.40) Therefore, a prudent approach to pre-
scription and careful monitoring of metabolic side effects 
is needed when using this antipsychotic to manage 
first-episode schizophrenia.
The introduction of new compounds for treating psy-
choses may affect the choice of the first antipsychotic drug 
after being diagnosed with schizophrenia. In our findings, 
paliperidone, an atypical antipsychotic medication that 
was newly approved in 2009, was the second most fre-
quently prescribed drug in 2010. Similarly, the use of ari-
piprazole, which had been commercialized in Korea after 
KFDA approval in 2004, was high in 2005 (23%, third 
most commonly used drug) and decreased to 11.5% in 
2010. Whereas the prescribing rate of olanzapine de-
creased substantially over a 5-year period, the use of ris-
peridone was not strongly influenced by the introduction 
of new antipsychotics and remained relatively steady. 
Consistent with our findings, olanzapine use decreased 
and risperidone use remained steady in a 10-year cohort 
study of newly diagnosed patients with schizophrenia as 
newly developed antipsychotics were introduced.21) 
Intensive marketing of new antipsychotics by the pharma-
ceutical companies may have influenced the observed 
prescription rate trends,41) and physicians may be more 
likely to try something new in hopes of maximizing 
outcomes. 
Clozapine has been shown to have advantages over other 
antipsychotics in terms of efficacy42) and effectiveness43), 
with comparable cost-effectiveness to that accepted for 
many medical interventions.44) However, in spite of the 
clinical guidelines, clozapine is used less and later than 
recommended, as shown in our findings. Moreover, recent 
studies45,46) indicate that the incidence and mortality of 
clozapine-induced agranulocytosis, the most feared side 
effect, could be lower than previously estimated. Another 
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cohort study47) reported that all-cause mortality due to clo-
zapine is substantially inferior to that associated with oth-
er antipsychotic drugs and recommended that the re-
strictions regarding the use of the drug be reevaluated. 
Although few studies have been carried out, randomized 
clinical trials with clozapine in treating first psychotic epi-
sodes have supported the superiority of clozapine over 
other antipsychotics.48,49) Therefore, clozapine should be 
considered when choosing antipsychotics for the early 
treatment of first-episode schizophrenic patients, espe-
cially in cases of non-response.50)
Although our data came from patients with non-affec-
tive and first-episode schizophrenia, we found a sig-
nificant increase in the prescription of mood stabilizers 
from 2005 to 2010, which is consistent with the increase in 
the prescription of mood stabilizers in other studies of 
first-episode psychosis.21,28) The increased use of mood 
stabilizers may be due to evidence implicating mood dis-
turbances in the disease burden and prognosis of schizo-
phrenic patients.51) The mood stabilizers may be used in 
conjunction with antipsychotics to control agitation and 
violence in the acute psychotic state.52) This intensified 
conjunctive therapy may be partly attributable to secular 
trends in the structure and delivery of psychiatric services 
(i.e., the general shift to voluntary psychiatric hospital-
ization or outpatient care). The revised mental health leg-
islation in Korea that took effect on March 22, 2009 limits 
involuntary admission through more stringent admission 
procedures, which may have influenced the significant de-
crease in the involuntary admission rate we observed be-
tween 2005 and 2010. Under voluntary admission, rapid 
tranquilization may be required using more active psycho-
pharmacological approaches. 
Several limitations of our study warrant consideration. 
First, although data were collected prospectively as part of 
the principal investigator’s regular clinical duties, our in-
vestigation was limited to a retrospective review metho-
dology. Second, we lacked information regarding illness 
severity and drug tolerability. Third, we performed our in-
vestigation at only a single residency-affiliated inpatient 
facility that carried more acute unstable patients with 
higher rates of involuntary admission, which may have 
biased the results toward higher-than-normal rates of 
high-dose prescriptions. Additionally, the small sample 
size of this study limits the generalizability of our 
findings. Finally, our observed rate of high-dose anti-
psychotic prescription could be somewhat overestimated. 
DDD, defined as the assumed average dose per day for 
maintenance treatment,19) has been criticized for promot-
ing subtherapeutic doses in the treatment of psychosis.53) 
Therefore, PDD/DDD ratios may be higher for stabilized 
patients immediately after hospital discharge than for out-
patients during the maintenance phase. 
The prescription of high-dose antipsychotics with anti-
psychotic polypharmacy is a common clinical practice for 
treating patients with chronic schizophrenia. This study 
investigating the initial treatment of first-episode schizo-
phrenia showed that the rates of excessive dosing were 
high in both 2005 and 2010, as more than one-third of pa-
tients received two or more antipsychotic agents in both 
years and antipsychotic polypharmacy was the main fac-
tor associated with high-dose antipsychotics use. However, 
the most common types of antipsychotics prescribed were 
different between the two years, and the use of mood sta-
bilizers significantly increased for non-affective schizo-
phrenia in 2010. Further prospective studies are needed to 
determine the optimal dosages of antipsychotics and the 
effects of concomitant medications during the early stage 
of psychosis.
The authors would like to thank all of the staff at 
Severance Mental Health Hospital for their assistance 
with this research.
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